Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

2,2'-diphenyl-3,3'-diindolylmethane: a potent compound induces apoptosis in breast cancer cells by inhibiting EGFR pathway.

Bhowmik A, Das N, Pal U, Mandal M, Bhattacharya S, Sarkar M, Jaisankar P, Maiti NC, Ghosh MK.

PLoS One. 2013;8(3):e59798. doi: 10.1371/journal.pone.0059798. Epub 2013 Mar 28.

2.

Indole-3-carbinol-induced death in cancer cells involves EGFR downregulation and is exacerbated in a 3D environment.

Moiseeva EP, Fox LH, Howells LM, Temple LA, Manson MM.

Apoptosis. 2006 May;11(5):799-812.

PMID:
16532375
3.

3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.

McGuire KP, Ngoubilly N, Neavyn M, Lanza-Jacoby S.

J Surg Res. 2006 May 15;132(2):208-13. Epub 2006 Mar 31.

PMID:
16580691
4.

Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action.

Wang S, Liu Q, Zhang Y, Liu K, Yu P, Liu K, Luan J, Duan H, Lu Z, Wang F, Wu E, Yagasaki K, Zhang G.

Mol Cancer. 2009 Oct 1;8:81. doi: 10.1186/1476-4598-8-81.

5.

Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.

Gupta P, Srivastava SK.

BMC Med. 2012 Jul 24;10:80. doi: 10.1186/1741-7015-10-80.

6.

EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.

Yao W, Feng D, Bian W, Yang L, Li Y, Yang Z, Xiong Y, Zheng J, Zhai R, He J.

Amino Acids. 2012 Nov;43(5):2027-35. doi: 10.1007/s00726-012-1277-z. Epub 2012 Apr 4.

7.

Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells.

Sarkar S, Rajput S, Tripathi AK, Mandal M.

Mol Cancer. 2013 Oct 20;12(1):122. doi: 10.1186/1476-4598-12-122.

8.

A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.

Zhan Y, Zhang Y, Liu C, Zhang J, Smith WW, Wang N, Chen Y, Zheng L, He L.

Cancer Prev Res (Phila). 2012 Jun;5(6):864-73. doi: 10.1158/1940-6207.CAPR-11-0575. Epub 2012 Apr 11.

9.
10.

Gold nanoparticle-conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2-mediated pathway in breast cancer.

Balakrishnan S, Bhat FA, Raja Singh P, Mukherjee S, Elumalai P, Das S, Patra CR, Arunakaran J.

Cell Prolif. 2016 Dec;49(6):678-697. doi: 10.1111/cpr.12296. Epub 2016 Sep 18.

PMID:
27641938
11.

Meso-dihydroguaiaretic acid induces apoptosis and inhibits cell migration via p38 activation and EGFR/Src/intergrin β3 downregulation in breast cancer cells.

Choi MS, Jeong HJ, Kang TH, Shin HM, Oh ST, Choi Y, Jeon S.

Life Sci. 2015 Nov 15;141:81-9. doi: 10.1016/j.lfs.2015.09.003. Epub 2015 Sep 14.

PMID:
26382595
12.

Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.

Saxena R, Fatima I, Chandra V, Blesson CS, Kharkwal G, Hussain MK, Hajela K, Roy BG, Dwivedi A.

Steroids. 2013 Nov;78(11):1071-86. doi: 10.1016/j.steroids.2013.07.004. Epub 2013 Jul 26.

PMID:
23891847
14.

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.

J Cell Physiol. 2006 May;207(2):420-7.

PMID:
16419029
15.

LYG-202 exerts antitumor effect on PI3K/Akt signaling pathway in human breast cancer cells.

Zhao Y, Wang X, Sun Y, Zhou Y, Yin Y, Ding Y, Li Z, Guo Q, Lu N.

Apoptosis. 2015 Sep;20(9):1253-69. doi: 10.1007/s10495-015-1145-x.

PMID:
26153346
16.

ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.

Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M.

Cancer Biol Ther. 2010 Apr 15;9(8):592-603. Epub 2010 Apr 4.

PMID:
20139705
17.

Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells.

Moon DO, Kim MO, Heo MS, Lee JD, Choi YH, Kim GY.

Arch Pharm Res. 2009 Oct;32(10):1351-60. doi: 10.1007/s12272-009-2002-7. Epub 2009 Nov 8.

PMID:
19898796
18.

AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells.

Rabi T, Huwiler A, Zangemeister-Wittke U.

Mol Carcinog. 2014 Jul;53(7):578-88. doi: 10.1002/mc.22012. Epub 2013 Mar 8.

PMID:
23475563
19.

The in vitro and in vivo anti-tumor effect of KO-202125, a sauristolactam derivative, as a novel epidermal growth factor receptor inhibitor in human breast cancer.

Oh M, Lee JY, Shin DH, Park JH, Oian T, Kim HJ, Cho SD, Oh SH, Min YK, Kong G.

Cancer Sci. 2011 Mar;102(3):597-604. doi: 10.1111/j.1349-7006.2010.01817.x. Epub 2011 Jan 10.

20.

Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative.

Chakravarti B, Siddiqui JA, Dwivedi SK, Deshpande S, Samanta K, Bhatta RS, Panda G, Prabhakar YS, Konwar R, Sanyal S, Chattopadhyay N.

Mol Cell Endocrinol. 2011 May 16;338(1-2):68-78. doi: 10.1016/j.mce.2011.03.012. Epub 2011 Mar 30.

PMID:
21457754

Supplemental Content

Support Center